Skip to main content
Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry n/a
Sector n/a
Employees n/a
CEO n/a
Address , ,
Phone n/a
Website n/a

Competitors

Company Name 3 Month
%Change
1 Year
%Change
No competitor information is available.

Statement Summary

as of 3:59 ET PM 11/24/2021
Total Assets (MRQ) n/a
Total Liabilities (MRQ) n/a
Shareholders’ Equity (MRQ) n/a
Total Revenue (Annual) 14.6 B
Net Income (Annual) n/a

Earnings And Estimates

as of 3:59 ET PM 11/24/2021

Current Qtr EPS Estimate n/a
Current FY EPS Estimate n/a
Long Term EPS Growth Estimate 24.78
Next Expected Earnings Date //

CODGF vs S&P 500

as of 11/24/2021
Relative To
S&P 500
CODGF
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 3:59 ET PM 11/24/2021
Fiscal Quarter Estimate Actual Surprise

Financial Strength

as of 3:59 ET PM 11/24/2021
Pre-Tax Margin 0.00
Net Margin 0.00
Operating Margin 0.00
Return On Equity 0.00
Return On Assets 0.00
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) n/a

Ratios

as of 3:59 PM ET 11/24/2021
Price/Earnings (TTM) 13.07
Price/Book (MRQ) 1.51
Price/Cash Flow (TTM) 5.14
Book Value (MRQ) 0.00
Quick Ratio (MRQ) 0.00
Current Ratio (MRQ) 0.00
Total Debt/Equity (MRQ) 0.00

Short Interest

as of 10:47 AM ET 11/26/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares n/a n/a
Short Interest Ratio n/a n/a
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 3:59 ET PM 11/24/2021
Current Qtr
(12/1969)
Next Qtr
(12/1969)
Consensus Estimate n/a n/a
# of Estimates n/a n/a
High Estimate n/a n/a
Low Estimate n/a n/a
Year Ago EPS n/a n/a
Year Over Year Growth Estimate n/a n/a
Current Yr
(12/1969)
Next Yr
(12/1969)
Consensus Estimate n/a n/a
# of Estimates n/a n/a
High Estimate n/a n/a
Low Estimate n/a n/a
Year Ago EPS n/a n/a
Year Over Year Growth Estimate n/a n/a
Current Qtr
(12/1969)
Next Qtr
(12/1969)
Current Year
(12/1969)
Next Year
(12/1969)
Consensus Estimate n/a n/a n/a n/a
# of Estimates n/a n/a n/a n/a
High Estimate n/a n/a n/a n/a
Low Estimate n/a n/a n/a n/a
Year Ago EPS n/a n/a n/a n/a
Year Over Year Growth Estimate n/a n/a n/a n/a

Insider Information Summary

as of n/a
% Insiders - n/a
% Remaining Total Shares - n/a
Current 1 Month
Net Insider Transaction n/a n/a
Shares Bought n/a n/a
Shares Sold n/a n/a

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

pexels-alexander-suhorucov-6457488

Paycheck Advance: How to Help Your Employees

As a small business owner, you might be faced with an employee who requests a paycheck advance. Below are some common practices for providing a payroll advance.

Facebook Meta Logo Lead

Facebook Owner Meta told by U.K. Antitrust Regulator to Sell Giphy

Facebook parent Meta has been order by the U.K.’s competition watchdog to sell GIF-sharing platform Giphy, which it bought in 2020 for a reported $400 million.

Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint

ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial

ImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.

Semiconductor Lead

Lam Research and KLA: 2 Must-Own Chip-Equipment Stocks

Amid the chip shortage, two key equipment stocks fly under the radar: Lam Research and KLA.

Merck Lead

Merck Covid-19 Pill to Be Reviewed by FDA Advisory Panel

Merck’s Covid-19 oral antiviral pill will be reviewed by an outside panel of advisors to the FDA on Tuesday, paving the way for potential authorization by year-end.

Moderna vaccine Lead

Moderna Stock Slumps, Regeneron Slides On Omicron Variant Efficacy Warnings

Moderna said its Covid vaccine would likely experience a 'material drop' in efficacy against Omicron, while Regeneron warned its antibody cocktail may also have reduced activity against the new variant.

Wall Street Lead

Moderna Warns on Omicron, Powell, Yellen Face Senate - 5 Things You Must Know

Stocks slump as Omicron concerns resurface; Moderna CEO cautions on vaccine efficacy against new variant; Powell and Yellen to testify before the Senate Banking Committee on CARES Act; FTC orders supply chain probe and cloud adoption software group HashiCorp seeks $13 billion valuation in upcoming Nasdaq IPO.

Wall Street Lead

Cramer's Mad Money Recap 11/29: Omicron, Amazon, Netflix

Jim Cramer reminds investors that the Omicron Covid variant doesn't pose systemic risks to the markets.

Lululemon Clothes Retail Lead

Lululemon Files Patent Lawsuit Against Peloton

Lululemon seeks injunction in leggings and sports bra design dispute with Peloton.